Literature DB >> 22386910

Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells.

Eleni Markoutsa1, Konstantina Papadia, Carla Clemente, Orfeu Flores, Sophia G Antimisiaris.   

Abstract

Anti-Aβ-MAb (Aβ-MAb)-decorated immunoliposomes (LIP) and dually decorated ones (dd-LIP) with OX-26 and Aβ-MAb were constructed. In both cases, the biotin-streptavidin ligation method was applied. All LIP types were characterized for size distribution, zeta potential, and integrity during incubation with serum proteins. Uptake and transcytosis of both LIP types and control vesicles by human brain endothelial hCMEC/D3 cells were measured. All LIP types had mean diameters below 150-200 nm and low polydispersity. Aβ-MAb-LIP uptake was higher than control PEGylated liposomes, while uptake of dd-LIP was similar to that of OX-26-LIP. Aβ-MAb-LIP and dd-LIP uptake increased significantly when cells were pre-incubated with Aβ1-42 peptides; OX-26-LIP uptake was not modulated. Transcytosis of Aβ-MAb-LIP through monolayers was 2.5 times higher when monolayers were pre-incubated with Aβ1-42. Transport of both probes, FITC-dextran and rhodamine-lipid, was equivalent, indicating that Aβ-MAb-LIP are transferred intact through the BBB model. The Aβ peptide-induced increase in binding (and transport) is regulated by the membrane receptors for Aβ1-42 peptides (RAGE), as proven after blocking RAGE by a specific MAb. Aβ1-42 peptides did not modulate the barrier tightness and integrity, as determined by transendothelial resistance and Lucifer Yellow permeability. Additionally, hCMEC/D3 cell viability was not affected by Aβ peptides or by Aβ-MAb-LIP.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386910     DOI: 10.1016/j.ejpb.2012.02.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  15 in total

1.  Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies.

Authors:  E Markoutsa; K Papadia; A D Giannou; M Spella; A Cagnotto; M Salmona; G T Stathopoulos; S G Antimisiaris
Journal:  Pharm Res       Date:  2013-12-13       Impact factor: 4.200

Review 2.  Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance.

Authors:  David J Mc Carthy; Meenakshi Malhotra; Aoife M O'Mahony; John F Cryan; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2014-12-02       Impact factor: 4.200

3.  Effect of IL-1β, TNF-α and IGF-1 on trans-endothelial passage of synthetic vectors through an in vitro vascular endothelial barrier of striated muscle.

Authors:  J P Gomez; C Gonçalves; C Pichon; P Midoux
Journal:  Gene Ther       Date:  2017-05-15       Impact factor: 5.250

Review 4.  Blood-brain barrier structure and function and the challenges for CNS drug delivery.

Authors:  N Joan Abbott
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

5.  Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia.

Authors:  Nino Muradashvili; Reeta Tyagi; Naira Metreveli; Suresh C Tyagi; David Lominadze
Journal:  J Cereb Blood Flow Metab       Date:  2014-05-28       Impact factor: 6.200

6.  In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.

Authors:  Iason T Papademetriou; Carmen Garnacho; Edward H Schuchman; Silvia Muro
Journal:  Biomaterials       Date:  2013-02-09       Impact factor: 12.479

7.  Sphingolipids affect fibrinogen-induced caveolar transcytosis and cerebrovascular permeability.

Authors:  Nino Muradashvili; Syed Jalal Khundmiri; Reeta Tyagi; Allison Gartung; William L Dean; Menq-Jer Lee; David Lominadze
Journal:  Am J Physiol Cell Physiol       Date:  2014-05-14       Impact factor: 4.249

8.  Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein.

Authors:  Joana A Loureiro; Bárbara Gomes; Manuel An Coelho; Maria do Carmo Pereira; Sandra Rocha
Journal:  Future Sci OA       Date:  2015-09-10

9.  Development of nanoemulsion for efficient brain parenteral delivery of cefuroxime: designs, characterizations, and pharmacokinetics.

Authors:  Siti Norhawani Harun; Syafinaz Amin Nordin; Siti Salwa Abd Gani; Ahmad Fuad Shamsuddin; Mahiran Basri; Hamidon Bin Basri
Journal:  Int J Nanomedicine       Date:  2018-04-27

Review 10.  Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities.

Authors:  Muhammad Ovais; Nashmia Zia; Irshad Ahmad; Ali Talha Khalil; Abida Raza; Muhammad Ayaz; Abdul Sadiq; Farhat Ullah; Zabta Khan Shinwari
Journal:  Front Aging Neurosci       Date:  2018-10-23       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.